Fresh findings from the landmark T-REx clinical trial released today by the University of Western Australia’s HealthSpan Institute highlight how patients using popular GLP-1 medications like tirzepatide can prevent therapy-induced muscle loss. While incretin-based weight-loss drugs dramatically reduce body fat, rapid weight reduction often compromises lean muscle mass and physical function. Researchers confirmed that structured resistance training preserves vital muscle strength and metabolic health during treatment, offering a clear clinical blueprint for healthier aging.
About the Author
